Members of the muscarinic acetylcholine receptor family (M 1 -M 5 ) are widely expressed in the central nervous system and in the body periphery (1-7). Central muscarinic receptors are known to play key roles in memory and learning as well as in the regulation of many sensory, motor, and autonomic processes (1-3). In the body periphery, muscarinic receptors mediate the well known activities of acetylcholine released from parasympathetic nerves (1-3).
Members of the muscarinic acetylcholine receptor family (M 1 -M 5 ) are widely expressed in the central nervous system and in the body periphery (1) (2) (3) (4) (5) (6) (7) . Central muscarinic receptors are known to play key roles in memory and learning as well as in the regulation of many sensory, motor, and autonomic processes (1) (2) (3) . In the body periphery, muscarinic receptors mediate the well known activities of acetylcholine released from parasympathetic nerves (1) (2) (3) .
Based on the overlapping expression patterns of the different muscarinic receptor subtypes (4-7) and the lack of ligands that display a high degree of receptor subtype selectivity (8, 9) , the precise functional roles of the individual muscarinic receptor species remain to be determined. To address this issue, we therefore decided to use gene-targeting technology to generate mouse lines deficient in individual muscarinic receptor subtypes. In this study, we present an initial pharmacologic analysis of a mouse line that lacks functional M 4 muscarinic receptors.
At the molecular level, the M 4 receptor subtype, like the structurally closely related M 2 receptor, couples to G proteins of the G i ͞G o family (8, 9) . M 4 receptors are expressed abundantly in the striatum (caudate-putamen) and are also present, though at lower levels, in several other brain regions including cerebral cortex and hippocampus (4-7, 10, 11) . In the striatum, a region known to be critically involved in extrapyramidal motor control, the M 4 as well as other muscarinic receptor subtypes are coexpressed with D1 and D2 dopamine receptors on striatal projection neurons (12) (13) (14) (15) (16) . Considerable evidence suggests that complex interactions between these two neurotransmitter receptor systems are critical for the proper regulation of motor control (2, 17, 18) . Consistent with this notion, the severe motor deficits observed in patients suffering from Parkinson's disease and other extrapyramidal motor disorders are thought to reflect an imbalance between muscarinic cholinergic and dopaminergic tone in the striatum (2, 17) . To shed light on the potential interactions of M 4 muscarinic receptors with the different dopamine receptor subtypes, we have investigated systematically the locomotor effects induced by administration of D1-and D2-selective ligands in wild-type and M 4 receptor knockout (KO) mice.
Interestingly, recent pharmacologic studies suggested that the M 4 receptor subtype may be responsible for mediating muscarinic receptor-dependent antinociception (19, 20) . Thus, another main focus of the present study was to study muscarinic agonistinduced analgesic effects in the M 4 receptor KO mice. In addition, we also examined the potential involvement of the M 4 receptor subtype in muscarinic receptor-mediated tremor, salivation, and hypothermia, three of the most striking effects caused by administration of centrally acting muscarinic agonists (21) .
We demonstrate that M 4 receptor-deficient mice show an increase in basal locomotor activity and are hypersensitive to the stimulatory locomotor effects of D1 receptor activation, indicative of a functional interaction between these two receptor systems. Moreover, we show that M 4 receptors do not play a pronounced role in mediating muscarinic receptor-dependent analgesia, tremor, hypothermia, and salivation.
MATERIALS AND METHODS
Gene Targeting. A murine M 4 muscarinic receptor clone was isolated from a 129SvJ mouse genomic library (Genome Systems) by hybridization with a PCR fragment encoding the central portion of the third intracellular loop. The M 4 targeting vector was derived from pPN2T (ref. 22) , which is characterized by the presence of two copies of the herpes simplex virus thymidine kinase gene (HSV-TK) (Fig. 1a) . The M 4 receptor coding sequence was disrupted by replacing a 0.55-kb BglII-XhoI genomic fragment (which encodes the region between the middle of the second transmembrane domain and the N terminus of the third intracellular loop) with the PGK-neomycin resistance gene (PGK-neo).
The targeting construct was linearized at a unique NotI site and introduced into TC1 (129 SvEv) mouse embryonic stem (ES) cells
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.
PNAS is available online at www.pnas.org. (23) by electroporation, followed by selection in G418 and gancyclovir. Colonies that survived the double-selection procedure were isolated and screened by Southern blotting for homologous recombination. This analysis showed that 13 of a total of 140 screened clones had been targeted properly. Positive ES cell clones were microinjected into C57BL͞6 blastocysts to generate chimeric offspring. Male chimeras were crossed with female CF-1 mice (Charles River Breeding Laboratories) to generate F 1 offspring. F 1 animals heterozygous for the M 4 receptor mutation then were intermated to produce homozygous M 4 receptor KO mice. All mice used in the present study were F 2 hybrids.
In Situ Hybridization. Twelve-micrometer-thick horizontal brain sections were processed for mRNA in situ hybridization histochemistry as described (24) . A 35 S-labeled ribonucleotide antisense probe was synthesized from the 0.55-kb BglII-XhoI genomic fragment (cloned into pBluescript) that was deleted during the construction of the M 4 targeting vector (Fig. 1a) .
Radioligand-Binding Studies. Mouse brains were removed, dissected, frozen immediately on dry ice, and stored at Ϫ70°C until use. To measure muscarinic receptor densities in different brain regions, radioligand-binding studies were carried out with membrane preparations essentially as described (21, 25 (26) .
Immunoprecipitation Assays. Muscarinic receptor subtypespecific rabbit polyclonal antisera were raised against nonconserved regions of the third cytoplasmic loops of the mouse receptor proteins in a fashion similar to that described by Levey et al. (7) . For immunoprecipitation studies, membranes derived from different mouse brain regions were incubated with 2 nM [ 3 H]QNB to label M 1 -M 5 muscarinic receptors. 3 [H]QNBlabeled receptors were solubilized with 1% digitonin and subjected to immunoprecipitation by M 2 or M 4 receptor-specific antisera by following a procedure described by Yasuda et al. (10) .
Neurochemistry. Mice were killed by decapitation, and striatal tissue was quickly dissected from brain and frozen on dry ice. Striatal acetylcholine, dopamine, and 3,4-dihydroxyphenyl acetic acid (DOPAC) levels were determined via HPLC with electrochemical detection by following a previously published procedure (27) .
Pharmacologic and Behavioral Studies. All studies were carried out with animals that were at least 3 months old. Mice were housed in a temperature-and humidity-controlled vivarium, which was kept on a 12-hr dark͞12-hr light cycle. Experiments were carried out with mice of either sex. Because the observed pharmacologic and behavioral responses (see below) were similar in male and female mice, data generally were pooled.
Oxotremorine (OXO)-induced tremor, salivation, and hypothermia were measured simultaneously in the same group of mice. Mice from each genotype were injected s.c. with vehicle (distilled water) or different doses of OXO. Body temperature, salivation, and tremor were assessed immediately before and 30 min after injections. Core body temperature was measured by a rectal thermometer (model BAT 8; Bailey Instruments, Saddle Brook, NJ). Salivation and tremor were scored by a trained observer on a scale of 0 (no salivation or tremor), 1 [moderate salivation (moisture on face only) or tremor (intermittent head and body tremor)], and 2 [marked salivation (moisture on face and chest) or tremor (nearly continuous whole body tremor)]. The data were expressed as percent effect, where the score for each mouse was expressed as a percentage of the maximum possible score (i.e., 2).
The tail-flick test was performed by immersing mouse tails in a 55°C water bath and measuring withdrawal latencies immediately before (baseline) and 30 min after OXO or vehicle injection (cut-off time: 10 sec). Data were expressed as percentage of maximum possible effect (MPE), where % MPE ϭ 100ϫ [(postdrug latency Ϫ baseline)͞(10 Ϫ baseline)].
The hot-plate test was carried out by using an electronically controlled hot-plate analgesia meter (model HP͞fj; Omnitech Electronics, Columbus, OH). The nociceptive threshold was defined as response latency to lick the front or hind paws after being placed on a 55°C hot plate, immediately before (baseline) and 30 min after OXO or vehicle injection (cut-off time: 30 sec). Data were expressed as percentage of MPE (ϭ 100ϫ [(postdrug latency Ϫ baseline)͞(30 Ϫ baseline)]).
To assess spontaneous locomotor activity, mice from each genotype were placed in polypropylene cages [24 ϫ 45 ϫ 15 cm (height)], and the number of photocell beam interruptions were counted for 60 min to monitor horizontal activity by using a Photobeam Activity System (San Diego Instruments, San Diego). In experiments involving drug injections, mice were placed into the locomotion boxes for a 30-min acclimatization period, followed by the s.c. administration of drugs and immediate monitoring of locomotor activity for the next 60 min. All experiments were performed during the light cycle between 9 a.m. and 12 p.m.
Drugs. The following drugs were used for injection experiments: apomorphine hydrochloride (Sigma), (Ϯ)-SKF 39383 hydrochloride (Research Biochemicals, Natick, MA), haloperidol (a gift from Janssen), SCH 23390 hydrochloride (a gift from Schering-Plough), oxotremorine sesquifumarate (Sigma), and (Ϫ)-quinpirole hydrochloride (Research Biochemicals). All drugs were dissolved in distilled water and injected s.c. in a volume of 10 ml͞kg.
RESULTS

Generation of M 4 Muscarinic
Receptor-Deficient Mice. The M 4 muscarinic receptor gene was inactivated in mouse TC1 (129SvEv) ES cells by replacing a segment of the receptor coding sequence (encoding the region between the middle of the second transmembrane domain and the N terminus of the third intracellular loop) with a neomycin-resistance cassette (Fig. 1a) . Properly targeted ES cell clones were used to generate chimeric mice. These animals then were crossed with CF-1 mice to generate F 1 offspring heterozygous (ϩ͞Ϫ) for the M 4 receptor mutation. Male and female F 1 heterozygotes were intercrossed to obtain wild-type (ϩ͞ϩ) as well as heterozygous (ϩ͞Ϫ) and homozygous (Ϫ͞Ϫ) M 4 receptor mutant mice, as demonstrated by Southern blotting (Fig. 1b) S-labeled antisense riboprobe corresponding in sequence to the segment of the receptor coding region deleted in the M 4 KO mice (Fig. 1a) was used as probe. Studies with brains derived from wild-type mice showed that M 4 transcripts were particularly abundant in higher brain regions such as cerebral cortex, striatum (caudateputamen), hippocampus, and olfactory bulb (Fig. 2) . As expected, only background staining was found when brains derived from M 4 Ϫ͞Ϫ mutant mice were analyzed, indicative of the absence of functional M 4 receptor transcripts.
In addition, radioligand-binding studies were carried out by using a saturating concentration (2 nM) of the nonselective muscarinic antagonist, [ (Fig.  3) . Use of the anti-M 2 antiserum demonstrated that M 2 receptor densities remained virtually unchanged in the M 4 receptor mutant mice, as compared with their wild-type littermates (Fig. 3) .
Tremor, Salivation, and Body Temperature Responses. To examine the potential involvement of the M 4 receptor subtype in mediating muscarinic receptor-dependent tremor, salivation, and hypothermia, wild-type and M 4 receptor mutant mice were injected with increasing doses of the centrally active, nonselective muscarinic agonist, OXO (0.01-0.3 mg͞kg s.c.). OXO administration resulted in dose-dependent whole-body tremor, salivation, and hypothermia (21) . Maximum responses usually were observed after administration of 0.3 mg͞kg OXO. In general, OXO dose-response curves for tremor, salivation, and hypothermia responses remained largely unaffected in the M 4 receptordeficient mutant mice, as compared with their wild-type littermates (n ϭ 16-20 for each dose and genotype) (data not shown).
Muscarinic Receptor-Mediated Analgesia. The tail-flick and hot-plate tests were used to examine the potential involvement of the M 4 receptor subtype in muscarinic receptor-mediated analgesia (Fig. 4) . Injection of OXO (0.01-0.3 mg͞kg s.c.) induced strong dose-dependent analgesic effects in wild-type control mice in both tests. As shown in Fig. 4 , M 4 receptor mutant mice displayed OXO-dependent analgesic responses that were very similar to those seen with their wild-type littermates.
Locomotor Activity Measurements. Coordinated locomotor activity depends on the proper balance of muscarinic cholinergic and dopaminergic neurotransmission in the striatum (2, 17, 18) . Because the M 4 receptor subtype is particularly abundant in the striatum, we initially examined whether the loss of M 4 receptors had any effect on spontaneous locomotor activity determined in an ''open-field'' test. We found that M 4 receptor-deficient M 4 Ϫ͞Ϫ mutant mice showed a significant increase in basal locomotor activity (by about 30% as compared with their wild-type littermates), as measured by the total number of consecutive photo-
FIG. 2.
In situ hybridization analysis of M4 receptor mRNA expression in wild-type and M4 receptor mutant mice. Horizontal brain sections obtained from mice of the indicated genotypes were analyzed. A 35 Slabeled ribonucleotide antisense probe corresponding in sequence to the genomic fragment that was deleted during the construction of the M4 targeting vector (see Fig. 1a ) was used as a probe. CPu, caudate-putamen; Cx, cerebral cortex; Hc, hippocampus; OB, olfactory bulb. (Fig. 5a ). Examination of the time course of this effect showed that the M 4 receptor KO mice were more active than their wild-type littermates during each 10-min interval of the 60-min observation period (Fig. 5b) . Previous studies have shown that the M 4 receptor subtype is colocalized with D1 and D2 dopamine receptors on striatal projection neurons (12) (13) (14) (15) (16) . We therefore wanted to study whether locomotor responses induced by injection of dopamine receptor agonists and antagonists were altered in M 4 Ϫ͞Ϫ mutant mice. In wild-type mice, injection of the nonselective dopaminergic agonist, apomorphine (0.3-10 mg͞kg s.c.), resulted in a bell-shaped dose-response curve, characterized by a modest increase in locomotor activity at the two intermediate doses (1 and 3 mg͞kg) (Fig. 6) . Strikingly, the stimulatory locomotor effects of apomorphine were enhanced greatly in M 4 receptor KO mice, an effect that was most pronounced at the two highest apomorphine doses used (Fig. 6) .
To examine whether the apomorphine-dependent hypermotility observed with the M 4 Ϫ͞Ϫ mutant mice involved the activation of D1 or D2 dopamine receptors, we also measured locomotor responses after administration of SKF 38393, an agonist selective for dopamine receptors of the D1 class (D1, D5), and of quinpirole, an agonist selective for dopamine receptors of the D2 class (D2, D3, and D4). In wild-type animals, SKF 38393 (3-56 mg͞kg s.c.) produced a dose-dependent increase in locomotor activity, whereas administration of quinpirole (0.003-3 mg͞kg s.c.) resulted in a dose-dependent inhibition of locomotor responses (Fig. 6) . Notably, the stimulatory responses to injection of the D1-type agonist SKF 38393 were found to be enhanced greatly in the M 4 receptor KO mice (Fig. 6 ). In contrast, the inhibitory locomotor responses induced by the D2-type agonist, quinpirole, were similar in wild-type and M 4 Ϫ͞Ϫ mutant mice (Fig. 6) . Taken together, these data indicate that D1 receptormediated increases in locomotor activity are potentiated in the absence of functional M 4 receptors.
We next measured locomotor responses induced by administration of the D1-type antagonist, SCH 23390 (0.003-0.3 mg͞kg s.c.), and of the D2-type antagonist, haloperidol (0.03-3 mg͞kg s.c.). Consistent with previous studies (28) (29) (30) , injection of either antagonist into wild-type mice resulted in a reduction in locomotor activity (Fig. 7) . SCH 23390-injected M 4 Ϫ͞Ϫ mutant mice displayed inhibitory locomotor responses similar to those observed with their wild-type littermates. On the other hand, haloperidol-dependent reduction of locomotor activity required higher haloperidol doses (Ն0.3 mg͞kg) in the M 4 receptor KO mice (Fig. 7) , probably because the locomotor-depressing effect of haloperidol was counteracted more effectively by stimulatory D1 receptors in the mutant mice lacking inhibitory M 4 receptors.
Determination of Striatal Dopamine Receptor Densities and Monoamine Levels. Radioligand-binding studies were carried out to exclude the possibility that the hyperlocomotor effects in M 4 Ϫ͞Ϫ mutant mice were caused by altered striatal dopamine receptor densities. Striatal membrane preparations derived from M 4 Ϫ͞Ϫ mutant mice and their wild-type littermates were incubated with saturating concentrations of the D1-type antagonist, In addition, striatal acetylcholine, dopamine, and DOPAC (a major dopamine metabolite) levels were determined via HPLCcoupled electrochemical detection. These studies did not reveal any significant differences in the tissue levels of these three monoamines (nmol͞g tissue; n ϭ 6): acetylcholine (ϩ͞ϩ, 11.3 Ϯ 0.9; Ϫ͞Ϫ, 9.8 Ϯ 0.9), dopamine (ϩ͞ϩ, 86.8 Ϯ 6.9; Ϫ͞Ϫ, 89.7 Ϯ 4.1), and DOPAC (ϩ͞ϩ, 6.95 Ϯ 0.59; Ϫ͞Ϫ, 5.95 Ϯ 0.34).
DISCUSSION
Centrally acting muscarinic agonists produce pronounced analgesic effects (31) (32) (33) (34) (35) , suggesting that such agents are of potential clinical usefulness as potent analgesic drugs. It has been proposed, based on in vivo pharmacologic studies, that muscarinic receptormediated analgesia is mediated by the M 4 subtype (19, 20) . However, we found that OXO-induced analgesic effects were affected little in M 4 receptor-deficient mice (Fig. 4) , suggesting that the M 4 subtype does not play a major role in mediating these effects in mice. Consistent with this observation, we reported recently that OXO-induced antinociception was reduced greatly in mice lacking functional M 2 muscarinic receptors (21), demonstrating that M 2 receptor stimulation is primarily responsible for muscarinic receptor-dependent analgesia. These findings highlight the usefulness of muscarinic receptor KO mice in assigning, in an unambiguous fashion, specific pharmacologic activities to defined muscarinic receptor subtypes.
OXO-injection experiments also showed that muscarinic receptor-mediated salivation, tremor, and hypothermia responses were similar in M 4 receptor mutant mice and their control littermates (data not shown). Similarly, muscarinic agonistinduced tremor and salivation also were observed in M 1 receptordeficient mice (36) . Interestingly, pharmacologic analysis of M 2 receptor KO mice showed that muscarinic agonist-dependent hypothermia and tremor are primarily (hypothermia) or exclusively (tremor) mediated by the M 2 subtype (21). Moreover, pharmacologic evidence suggests that muscarinic receptors mediating salivary (glandular) secretion are predominantly of the M 3 subtype (1-3, 8) .
The M 4 muscarinic receptor is expressed abundantly in the striatum (4-7, 10, 11), a region known to be critically involved in the regulation of extrapyramidal motor activity. A proper balance between striatal muscarinic cholinergic and dopaminergic neurotransmission is required for coordinated locomotor control (2, 17, 18) . Consistent with this notion, both dopamine receptor agonists and muscarinic receptor antagonists are clinically useful in the treatment of Parkinson's disease, a movement disorder caused by the loss of striatal dopamine (2, 17) . In situ hybridization histochemical studies (12) (13) (14) (15) (16) have shown that D1 and D2 dopamine receptors are expressed abundantly in the striatum, where they are localized on different subpopulations of spiny projection neurons that comprise more than 90% of striatal neurons. Whereas the D1 subtype is localized to striatal neurons that project directly to the substantia nigra (striatonigral pathway), the D2 subtype is expressed primarily by striatal neurons that project to the globus pallidus (striatopallidal pathway). Interestingly, almost all D1 receptor-expressing striatal projection neurons also express M 4 (as well as M 1 ) muscarinic receptors, whereas less than half of the D2 receptor-expressing striatal projection neurons express the M 4 subtype (13, 16) . The source of acetylcholine acting on these striatal muscarinic receptors are the large, striatal cholinergic interneurons that are known to be tonically active (reviewed in ref. 18 ). To study the potential modulatory role of the M 4 receptor subtype in dopamine receptor-dependent regulation of locomotor activity, we therefore examined locomotor responses to administration of different dopamine receptor agonists and antagonists in wild-type and M 4 receptor-deficient mice.
We initially demonstrated that M 4 receptor KO mice showed a significant increase in basal locomotor activity (Fig. 5) . Moreover, the locomotor stimulatory effects of apomorphine, a nonselective dopamine receptor agonist, and SKF 38393, a selective D1-type receptor agonist, were enhanced greatly in M 4 receptordeficient mice (Fig. 6) . Given the high abundance of D1 dopa- mine and M 4 muscarinic receptors in the striatum, their colocalization on striatonigral projection neurons, and the known importance of these neurons in the regulation of locomotor activity, it is likely that the increased locomotor responses observed with the M 4 receptor KO mice are, in fact, a result of altered striatal activity.
At a cellular level, D1 dopamine and M 4 muscarinic receptors mediate opposing biochemical effects, with D1 receptor stimulation leading to an increase in adenylyl cyclase activity (37) and M 4 receptor activation resulting in an inhibition of adenylyl cyclase (8, 9) . Moreover, Onali and coworkers (38, 39) demonstrated that D1 receptor-mediated increases in cAMP levels in striatal membrane preparations can be inhibited by concomitant stimulation of muscarinic receptors, which are probably of the M 4 subtype. These observations suggest a possible molecular mechanism by which M 4 receptors located on striatonigral projection neurons can counteract the increase in neuronal activity after D1 receptor activation (18) . It is likely that the increased locomotor responses displayed by the M 4 receptor-deficient mice are caused by an increased activity of the striatonigral pathway because of the lack of inhibitory striatal M 4 receptors.
It should be noted that all mice analyzed in this study (as well as in most other studies using gene-targeted mice) were of a mixed genetic background (129SvEv͞CF-1 hybrids). As discussed by Gerlai (40) , caution must be exercised in properly interpreting the phenotypical changes observed in KO mice of such genetic background. However, it is known that the 129SvEv mice, from which the targeted ES cells were derived, display reduced rather than increased locomotor activity (40, 41) . This observation virtually excludes the possibility that the observed increases in locomotor activity observed with the M 4 receptor-deficient mice are caused by 129SvEv genes that are linked to the KO locus.
Studies with pirenzepine and other muscarinic antagonists of limited receptor subtype selectivity suggest that M 1 receptors may play a role in higher cognitive functions such as memory and learning (1, 3) . However, virtually all antagonists that display high affinity for M 1 receptors also show high affinity for M 4 receptors (8) . The availability of the M 4 receptor KO mice therefore will offer the opportunity to study the possible involvement of M 4 receptors in memory and learning processes.
Taken together, our findings suggest that the clinical usefulness of muscarinic antagonists in improving locomotor deficits in patients suffering from Parkinson's disease and other extrapyramidal motor disorders is due, at least in part, to the blockade of inhibitory striatal M 4 muscarinic receptors. The development of centrally acting, selective M 4 receptor antagonists therefore remains an attractive therapeutic goal, because such agents are predicted to lack most of the bothersome side effects associated with the use of classical nonselective muscarinic antagonists, including dry mouth, blurred vision, and cognitive impairment (2) . The M 4 receptor-deficient mice described here should serve as a valuable tool for studying the role of the M 4 muscarinic receptor in striatal function and the regulation of extrapyramidal motor control.
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